Trials (National Institute of Oncology): Revision history

14 December 2025

• curprev 20:4020:40, 14 December 2025‎ Francine talk contribs‎ 56,829 bytes +173‎ No edit summary undo

6 December 2025

• curprev 12:4212:42, 6 December 2025‎ Lucas talk contribs‎ m 56,656 bytes +1,701‎ Update categories. undo

3 December 2025

• curprev 03:5303:53, 3 December 2025‎ Larysse talk contribs‎ 54,955 bytes +7‎ No edit summary undo

2 December 2025

• curprev 14:0014:00, 2 December 2025‎ Lucas talk contribs‎ m 54,948 bytes +120‎ Update categories. undo

5 November 2024

• curprev 16:0116:01, 5 November 2024‎ Victor talk contribs‎ 54,828 bytes +12‎ No edit summary undo

4 December 2023

• curprev 14:0814:08, 4 December 2023‎ Francine talk contribs‎ 54,816 bytes +54,816‎ Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to National Institute of Oncology page '''NCTID''': NCT05169567 '''Title''': Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer '''Study Summary''': This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast ca..."